JP2010534682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534682A5 JP2010534682A5 JP2010518424A JP2010518424A JP2010534682A5 JP 2010534682 A5 JP2010534682 A5 JP 2010534682A5 JP 2010518424 A JP2010518424 A JP 2010518424A JP 2010518424 A JP2010518424 A JP 2010518424A JP 2010534682 A5 JP2010534682 A5 JP 2010534682A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- composition
- cancer
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 68
- 206010028980 Neoplasm Diseases 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 62
- -1 trifluoromethylcarbonyl Chemical group 0.000 claims description 60
- 201000011510 cancer Diseases 0.000 claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 42
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 30
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 28
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 28
- 229940124647 MEK inhibitor Drugs 0.000 claims description 28
- 125000002883 imidazolyl group Chemical group 0.000 claims description 28
- 150000002148 esters Chemical class 0.000 claims description 24
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 24
- 230000035772 mutation Effects 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 101150056950 Ntrk2 gene Proteins 0.000 claims description 21
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 14
- 125000004193 piperazinyl group Chemical group 0.000 claims description 14
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 14
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims description 12
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims description 12
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 10
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 10
- 102000009076 src-Family Kinases Human genes 0.000 claims description 8
- 108010087686 src-Family Kinases Proteins 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 230000008499 blood brain barrier function Effects 0.000 claims description 6
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 6
- 201000007455 central nervous system cancer Diseases 0.000 claims description 6
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 4
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940044683 chemotherapy drug Drugs 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229960003685 imatinib mesylate Drugs 0.000 claims description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 102220198325 rs1057520025 Human genes 0.000 claims description 2
- 102220198339 rs1057520026 Human genes 0.000 claims description 2
- 102200039431 rs121913488 Human genes 0.000 claims description 2
- 102220197934 rs376588714 Human genes 0.000 claims description 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 201000007983 brain glioma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 0 C*[C@]([C@](C)O1)OC1=O Chemical compound C*[C@]([C@](C)O1)OC1=O 0.000 description 5
- VWIIJDNADIEEDB-UHFFFAOYSA-N CN(CCO1)C1=O Chemical compound CN(CCO1)C1=O VWIIJDNADIEEDB-UHFFFAOYSA-N 0.000 description 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- JTPZTKBRUCILQD-UHFFFAOYSA-N CN(CCN1)C1=O Chemical compound CN(CCN1)C1=O JTPZTKBRUCILQD-UHFFFAOYSA-N 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95190607P | 2007-07-25 | 2007-07-25 | |
| US95190107P | 2007-07-25 | 2007-07-25 | |
| US60/951,906 | 2007-07-25 | ||
| US60/951,901 | 2007-07-25 | ||
| US2919608P | 2008-02-15 | 2008-02-15 | |
| US61/029,196 | 2008-02-15 | ||
| PCT/US2008/071256 WO2009015368A2 (en) | 2007-07-25 | 2008-07-25 | Multikinase inhibitors for use in the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013114011A Division JP2013189458A (ja) | 2007-07-25 | 2013-05-30 | 癌の処置において使用するための多キナーゼインヒビター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010534682A JP2010534682A (ja) | 2010-11-11 |
| JP2010534682A5 true JP2010534682A5 (enExample) | 2011-08-25 |
| JP5484327B2 JP5484327B2 (ja) | 2014-05-07 |
Family
ID=40121184
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518424A Active JP5484327B2 (ja) | 2007-07-25 | 2008-07-25 | 癌の処置において使用するための多キナーゼインヒビター |
| JP2013114011A Pending JP2013189458A (ja) | 2007-07-25 | 2013-05-30 | 癌の処置において使用するための多キナーゼインヒビター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013114011A Pending JP2013189458A (ja) | 2007-07-25 | 2013-05-30 | 癌の処置において使用するための多キナーゼインヒビター |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8609640B2 (enExample) |
| EP (1) | EP2182941B1 (enExample) |
| JP (2) | JP5484327B2 (enExample) |
| KR (3) | KR101721161B1 (enExample) |
| CN (2) | CN101778627B (enExample) |
| AU (1) | AU2008279027B8 (enExample) |
| CA (1) | CA2698271C (enExample) |
| ES (1) | ES2670423T3 (enExample) |
| IL (2) | IL202307A (enExample) |
| WO (1) | WO2009015368A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101210018B1 (ko) * | 2002-03-08 | 2012-12-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 약물로서 유용한 거대고리 화합물 |
| ES2670423T3 (es) | 2007-07-25 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Inhibidores de multicinasas para uso en el tratamiento de cáncer |
| CA2704048A1 (en) * | 2007-10-29 | 2009-05-07 | Eisai R & D Management Co., Ltd. | Methods for prognosing the ability of a zearalenone analog compound to treat cancer |
| MX2010005999A (es) * | 2007-12-07 | 2010-06-23 | Eisai R&D Man Co Ltd | Intermediarios en la sintesis de analogos de macrolidos de zearalenona. |
| US8426418B2 (en) | 2010-08-27 | 2013-04-23 | CollabRx Inc. | Method to treat melanoma in BRAF inhibitor-resistant subjects |
| WO2014208774A1 (en) * | 2013-06-26 | 2014-12-31 | Eisai R&D Management Co., Ltd. | Use of eribulin and lenvatinib as combination therapy for treatment of cancer |
| DK3039424T3 (da) * | 2013-08-28 | 2020-08-31 | Crown Bioscience Inc Taicang | Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse |
| WO2015181628A1 (en) * | 2014-05-27 | 2015-12-03 | Eisai R&D Management Co., Ltd. | Treatment of acute myeloid leukemia with an hck inhibitor |
| WO2022053130A1 (en) * | 2020-09-09 | 2022-03-17 | Sid Alex Group, S.R.O. | Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9225396D0 (en) | 1992-12-04 | 1993-01-27 | Sandoz Ltd | Improvements in or relating to organic compounds |
| JPH0840893A (ja) | 1993-08-31 | 1996-02-13 | Takeda Chem Ind Ltd | インターロイキン−１産生抑制剤 |
| DE4420930C2 (de) | 1994-06-16 | 1997-05-22 | Daimler Benz Ag | Vorrichtung und Verfahren zum Steuern einer selbsttätigen Schaltvorrichtung eines Gangwechselgetriebes eines Kraftfahrzeuges |
| US5795910A (en) | 1994-10-28 | 1998-08-18 | Cor Therapeutics, Inc. | Method and compositions for inhibiting protein kinases |
| US5727726A (en) * | 1996-06-14 | 1998-03-17 | Newco Pneumatic Corp. | Cassette assembly for a stapling mechanism |
| AU6678398A (en) | 1997-02-27 | 1998-09-18 | Ana Maria Garcia | Inhibitors of isoprenyl transferase |
| GB2323845A (en) | 1997-03-31 | 1998-10-07 | Merck & Co Inc | MEK inhibiting lactones |
| WO2000038674A1 (en) | 1998-12-24 | 2000-07-06 | Novation Pharmaceuticals Inc. | COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR |
| GB9828709D0 (en) | 1998-12-24 | 1999-02-17 | Novartis Ag | Assay |
| KR20020000554A (ko) * | 1999-03-29 | 2002-01-05 | 윌슨, 로엔스 알. | 백혈병 치료방법 |
| WO2001036003A2 (en) | 1999-11-15 | 2001-05-25 | Drug Innovation & Design, Inc. | Selective cellular targeting: multifunctional delivery vehicles |
| MXPA02006778A (es) | 2000-01-12 | 2004-04-05 | Ventana Inc | Metodo para determinar la respuesta a una terapia de cancer. |
| EP1301794B1 (en) | 2000-04-14 | 2009-04-01 | Ventana Medical Systems, Inc. | Method for quantification of akt protein expression |
| JP2001294527A (ja) | 2000-04-14 | 2001-10-23 | Ajinomoto Co Inc | Ｔｈ２反応に特異的な免疫寛容誘導剤 |
| JP2004292314A (ja) | 2000-12-14 | 2004-10-21 | Chugai Pharmaceut Co Ltd | ケラチノサイト増殖抑制剤 |
| JP2004292315A (ja) | 2000-12-14 | 2004-10-21 | Chugai Pharmaceut Co Ltd | Ｔａｋ１阻害剤 |
| US7071164B2 (en) | 2001-08-16 | 2006-07-04 | Kimberly-Clark Worldwide, Inc. | Anti-cancer and wound healing compounds |
| EP1427810B9 (en) | 2001-08-21 | 2012-04-25 | Ventana Medical Systems, Inc. | Method and quantification assay for determining c-kit/scf/pakt status |
| NZ532780A (en) | 2001-12-21 | 2006-10-27 | Wellcome Trust | Isolated naturally occurring mutant human B-Raf polypeptides and nucleic acids encoding them |
| US20040096855A1 (en) | 2001-12-24 | 2004-05-20 | Michael Stratton | Genes |
| KR101210018B1 (ko) * | 2002-03-08 | 2012-12-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 약물로서 유용한 거대고리 화합물 |
| US7915306B2 (en) | 2002-03-08 | 2011-03-29 | Eisai Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| BR122016015715B8 (pt) | 2003-07-23 | 2021-05-25 | Bayer Healthcare Llc | composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico |
| AU2003286447A1 (en) | 2003-10-16 | 2004-06-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatments for inhibiting development and progression of nevi and melanoma having braf mutations |
| US20050214325A1 (en) | 2004-03-26 | 2005-09-29 | Vvii Newco 2003, Inc. | Compositions and methods to increase the effect of a neurotoxin treatment |
| CN101389345A (zh) | 2004-03-19 | 2009-03-18 | 宾州研究基金会 | 治疗黑素瘤的组合方法和组合物 |
| JP2007530654A (ja) | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
| CA2569277A1 (en) | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
| EP1794137A4 (en) * | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | SPECIFIC KINASE INHIBITORS |
| US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| US7812143B2 (en) | 2006-03-31 | 2010-10-12 | Memorial Sloan-Kettering Cancer Center | Biomarkers for cancer treatment |
| ES2670423T3 (es) | 2007-07-25 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Inhibidores de multicinasas para uso en el tratamiento de cáncer |
| CA2704048A1 (en) | 2007-10-29 | 2009-05-07 | Eisai R & D Management Co., Ltd. | Methods for prognosing the ability of a zearalenone analog compound to treat cancer |
| MX2010005999A (es) | 2007-12-07 | 2010-06-23 | Eisai R&D Man Co Ltd | Intermediarios en la sintesis de analogos de macrolidos de zearalenona. |
| US8578879B2 (en) * | 2009-07-29 | 2013-11-12 | Applied Materials, Inc. | Apparatus for VHF impedance match tuning |
-
2008
- 2008-07-25 ES ES08796672.7T patent/ES2670423T3/es active Active
- 2008-07-25 CN CN200880023760.7A patent/CN101778627B/zh active Active
- 2008-07-25 KR KR1020167028439A patent/KR101721161B1/ko active Active
- 2008-07-25 CN CN201610165747.1A patent/CN105748465A/zh active Pending
- 2008-07-25 AU AU2008279027A patent/AU2008279027B8/en active Active
- 2008-07-25 EP EP08796672.7A patent/EP2182941B1/en active Active
- 2008-07-25 CA CA2698271A patent/CA2698271C/en active Active
- 2008-07-25 US US12/180,408 patent/US8609640B2/en active Active
- 2008-07-25 JP JP2010518424A patent/JP5484327B2/ja active Active
- 2008-07-25 KR KR1020107004170A patent/KR101573026B1/ko active Active
- 2008-07-25 KR KR1020157033387A patent/KR101667960B1/ko active Active
- 2008-07-25 WO PCT/US2008/071256 patent/WO2009015368A2/en not_active Ceased
-
2009
- 2009-11-24 IL IL202307A patent/IL202307A/en active IP Right Grant
-
2013
- 2013-03-11 US US13/794,635 patent/US8937056B2/en active Active
- 2013-05-30 JP JP2013114011A patent/JP2013189458A/ja active Pending
-
2015
- 2015-01-13 US US14/595,746 patent/US20150182496A1/en not_active Abandoned
-
2016
- 2016-08-11 IL IL247230A patent/IL247230A/en active IP Right Grant
-
2018
- 2018-04-23 US US15/960,259 patent/US11160783B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534682A5 (enExample) | ||
| RU2597844C2 (ru) | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака | |
| TWI782906B (zh) | 惡性腫瘤治療用製劑及組合物 | |
| JP2020514311A5 (enExample) | ||
| CN105120663B (zh) | 用于利用羧胺三唑乳清酸盐治疗对先前化学治疗药物和靶向药物具有获得性耐药性的癌症的方法和组合物 | |
| JP2006503919A5 (enExample) | ||
| RU2357734C2 (ru) | КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА mGluR2 И ИНГИБИТОРА ФЕРМЕНТА AChE ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И/ИЛИ ХРОНИЧЕСКИХ НЕВРОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ | |
| US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| CN1511036A (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| HK1219879A1 (zh) | 用於治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合 | |
| RU2007145932A (ru) | Способ лечения устойчивого к лекарственным средствам рака | |
| CA2944255C (en) | New derivatives of cephalosporin for treating cancer | |
| CN114173785B (zh) | 用于治疗非小细胞肺癌的氨基吡啶衍生物 | |
| KR20210099022A (ko) | 약제학적 방법 | |
| CN116672345A (zh) | Parp抑制剂和细胞毒性剂的联合产品及其用途 | |
| JP7227968B2 (ja) | 抗腫瘍剤及び腫瘍治療方法 | |
| WO2024088193A1 (en) | Combination of aurora a and parp inhibitors for treatment of cancers | |
| WO2025083565A1 (en) | Phenotype and genotype target-based small molecule inhibitors in cancers | |
| JP2014034534A (ja) | ＨＳＰ９０阻害剤とｍＴＯＲ阻害剤の組み合わせ | |
| CN117794548A (zh) | 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂 | |
| JP2022046903A (ja) | びまん性胃がんの治療剤 | |
| RU2007131104A (ru) | Соединения, предназначенные для использования в фармацевтике | |
| JP2014091712A (ja) | Ｈｓｐ９０阻害剤と抗腫瘍性タキサン化合物との組み合わせ | |
| CN101198253A (zh) | 治疗癌症的组合、方法和组合物 |